Our CE IVD Products
SPOT-itTM
TREC & KREC
Screening Kit

SPOT-it™ TREC & KREC Screening kit is an in vitro diagnostic (IVD) kit intended for newborn screening for severe combined immunodeficiency (SCID) and agammaglobulinemia (XLA).
The kit identifies newborns potentially affected by SCID, characterized by a lack of mature T-cells or both T- and B-cells, and XLA, marked by an absence of mature B-cells.

Multiplex Screening
Newborn screening for SCID and XLA from a single Dried Blood Spot (DBS) punch.

The SPOT-it™ TREC & KREC Screening kit detects three essential markers — TREC, KREC, and Beta-actin (ACTB) — to screen for Severe Combined Immunodeficiency (SCID) and X-linked Agammaglobulinemia (XLA) using a single DBS punch.
Newborns with certain immunodeficiencies, including SCID, often show a significant reduction or absence of TREC copies, making TREC a key indicator for SCID.
KRECs, produced during B-cell maturation, provide insights into B-cell levels. A lack of KRECs alongside low TREC levels suggests SCID affecting both T- and B-cells, while a low KREC level with normal TREC may indicate XLA.
The ACTB gene, encoding Beta-actin protein, serves as an internal control to verify sample quality and assay performance.
Diagnosis shall be made by healthcare professionals through confirmatory testing, according to local requirements or recommendations.
Quick Assay
Information
SPOT-itTM
TREC & KREC
Screening Kits
Reliable and accessible in vitro diagnostic assays manufactured in Sweden
01
Multiplex qPCR test method
Multiplex SCID and XLA screening in one assay with real-time PCR technology.
02
Quick procedure
From Dried Blood Spot (DBS) to screening result within 3 hours, with no manual samples transfer needed.
03
Easy handling
Innovative plate-stacking method enables efficient liquid transfer.
04
No need for separate clean room
No need for separate clean room for MasterMix preparation.
05
Trusted kits
Used in national screening programs in multiple European countries since 2018.
06
CE-marked
Certified for in vitro diagnostic use in Europe.

Discover how the assay works
The test is intended for use by laboratory professionals to aid in identifying newborns, who potentially suffer from SCID and XLA.

Sample distribution
Distribute a 3.2 mm diameter punch from each Dried Blood Spot (DBS) sample into the SPOT-it™ Filter Plate.

Rinse Dried Blood Spots
Samples are rinsed and rehydrated to remove hemoglobin and other impurities.

Elution of the DNA
Transfer rinsed punches into the pre-filled Elution Plate using centrifugation and plate-stacking technology. DNA is then eluted by the heating process.

qPCR Amplification
Transfer the eluted DNA to the pre-filled qPCR Plate using centrifugation and plate-stacking technology; and launch the qPCR run.

Result Interpretation
Understand results rapidly by visualizing the data, and verify control parameters.

SCID and XLA screenings are performed by semi-quantification of T-TREC and KREC. DNA is extracted from 3.2 mm fresh, dried blood spot (DBS) sampled on filter paper.
Erna Domsgen, PhD
CEO at ImmunoIVD
Product details

Product name:
SPOT-it™ TREC & KREC Screening Kit
Description:
Simultaneous screening for SCID and XLA
Product Code | Format | Samples per kit |
---|---|---|
4-2015-TK | 4 x 96-well plate | 324 |
12-2015-TK | 12 x 96-well plate | 972 |
Other products

An in vitro diagnostic (IVD) kit intended for newborn screening for severe combined immunodeficiency (SCID).
Learn More
An in vitro diagnostic (IVD) kit intended for newborn screening for severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA) in newborns.
Learn More
An in vitro diagnostic (IVD) kit intended for newborn screening for severe combined immunodeficiency (SCID), agammaglobulinemia (XLA), and spinal muscular atrophy (SMA) in newborns.
Learn MoreInterested in Our Products?